Cascade Bio secures $6M to scale breakthrough biocatalysts
Cascade Bio, a Թ of Colorado Boulder spinout enabling enzyme-based processes, has secured $6 million to accelerate the shift from petrochemicals to biomanufacturing. The funding includes $3.2 million in non-dilutive funding from the U.S. National Science Foundation (NSF). With this investment, Cascade will expand delivery of its breakthrough biocatalysts.
Business Wire: Cascade Bio Secures $6M
The funding includes a $2.8M seed round led by Endurance28 with participation from Stray Dog Capital, 1Flourish, Range Ventures, 10VC, and Amplify plus $3.2M in nondilutive funding from the U.S. National Science Foundation (NSF) through the Advancing Cell-Free Systems Toward Increased Range of Use-Inspired Applications (NSF CFIRE) initiative and an SBIR Phase II award.
The Թ of Colorado Connection
Cascade Bio’s proprietary enzyme immobilization technology, dubbed “Body Armor,” acts as a cushion for the enzyme, enabling it to last longer, withstand more challenging conditions, and work across a wider operating window than other cell-free solutions. The technology was invented by co-founder while a graduate student in the CU Boulder laboratories of (CU Boulder Chemical and Biological Engineering) and (CU Boulder Chemical and Biological Engineering).
The Newsroom
For marketing and communication inquiries or news tips, contact Daniel Leonard,senior marketing and communications specialist for Venture Partners at CU Boulder.
For media inquiries, please visit .